Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Name: Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Published: 2014
License: Public Domain

Sierra Oncology LLC - a GSK company · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

egfr mutated egfr tki naive metastatic nsclc, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Related documents